1. Home
  2. OGN vs NRIX Comparison

OGN vs NRIX Comparison

Compare OGN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Organon & Co.

OGN

Organon & Co.

HOLD

Current Price

$13.43

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$17.12

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OGN
NRIX
Founded
1923
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
OGN
NRIX
Price
$13.43
$17.12
Analyst Decision
Hold
Strong Buy
Analyst Count
5
12
Target Price
$11.40
$30.50
AVG Volume (30 Days)
2.6M
2.8M
Earning Date
05-07-2026
04-08-2026
Dividend Yield
0.60%
N/A
EPS Growth
N/A
N/A
EPS
0.55
N/A
Revenue
$6,216,000,000.00
$76,987,000.00
Revenue This Year
$0.45
N/A
Revenue Next Year
$1.67
$48.05
P/E Ratio
$24.42
N/A
Revenue Growth
N/A
99.31
52 Week Low
$5.69
$8.20
52 Week High
$13.49
$22.50

Technical Indicators

Market Signals
Indicator
OGN
NRIX
Relative Strength Index (RSI) 72.03 59.72
Support Level $10.05 $17.21
Resistance Level $13.46 $19.98
Average True Range (ATR) 0.05 1.34
MACD -0.11 0.15
Stochastic Oscillator 57.14 70.88

Price Performance

Historical Comparison
OGN
NRIX

About OGN Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: